Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

Leukemia

Volumn 28, Issue 9, 2014, Pages 1885-1891

  Corradini, P ^a,b   Vitolo, U ^c   Rambaldi, A ^d   Miceli, R ^a   Patriarca, F ^e   Gallamini, A ^f   Olivieri, A ^g   Benedetti, F ^h   Todeschini, G ^h   Rossi, G ⁱ   Salvi, F ^j   Bruno, B ^c   Baldini, L ^b   Ferreri, A ^k   Patti, C ^l   Tarella, C ^m   Pileri, S ⁿ   Dodero, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f S CROCE E CARLE HOSPITAL   (Italy)

^g Azienda Ospedaliera Umberto I   (Italy)

^h Policlinico GB Rossi   (Italy)

ⁱ Ospedale Civile di Brescia   (Italy)

^j Ospedale di Alessandria   (Italy)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l Azienda Ospedali Riuniti Villa Sofia Cervello   (Italy)

^m MAURIZIANO HOSPITAL   (Italy)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CAUSE OF DEATH; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENCEPHALITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFECTIOUS COMPLICATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VIRUS REACTIVATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84908319588     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.79     Document Type: Article

References (34)

1. Foss FM, Zinzani PL, Vose GM, Gascoyne RD, Rosen ST, Tobinai K., et al. Peripheral T-cell lymphomas. Blood. 2011; 117: 6756-6767
2. International T cell lymphomas Project. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-4130
3. Schmitz N, Tru?mper L, Ziepert M, Nickelsen M, Ho AD, Metzner B., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116: 3418-3425
4. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY., et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006; 12: 7174-7179
5. Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T. CD52 expression in peripheral T-cell lymphomas determined by combine immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009; 50: 1010-1016
6. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007; 110: 2316-2323
7. Kluin-Nelemans HC, Kooy MM, Lugtenburg PJ, Van Putten WLJ, Luten M, Oudejans J., et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011; 22: 1595-1600
8. Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007; 60: 129-134
9. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P., et al. Long-Term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006; 20: 1533-1538
10. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The GelTamo Study Group. Eur J Haematol. 2007; 79: 32-38
11. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stemcell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008; 19: 958-963
12. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009; 27: 106-113
13. D'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson A., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30: 3093-3099
14. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M., et al. Graft-versuslymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004; 22: 2172-2176
15. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/ refractory peripheral T-cell lymphomas: long-Term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012; 26: 520-526
16. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M., et al. Graftversus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Socie? te? Francaise de Greffe de Moe? lle et de The?rapie Cellulaire. J Clin Oncol. 2008; 26: 2264-2271
17. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001
18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008
19. Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C., et al. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer. 2005; 104: 555-560
20. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F., et al. Reducedintensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002; 99: 75-82
21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM., et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10
23. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154
24. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001; 28: 1001-1011
25. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American Institution by the WHO classification. Ann Oncol. 2004; 15: 1467-1475
26. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ., et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-Arm, phase 2 trial. Eur J Cancer. 2012; 48: 3223-3331
27. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N., et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T-cell lymphoma. Biol Blood Marrow Transplant. 2013; 19: 602-606
28. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS., et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013; 31: 3100-3109
29. Lemonnier F, Couronne? L, Parrens M, Jais JP, Travert M, Lamant L., et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012; 120: 1466-1469
30. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F., et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013; 31: 3019-3025
31. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013; 31: 104-110
32. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182-1189
33. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30: 631-636
34. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic largecell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190-2196